SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.32+0.4%12:54 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Bong who wrote (1941)11/6/2000 8:59:22 AM
From: scott_jiminez  Read Replies (2) of 52153
 
Mark - responding to your questions (regarding Hypertension Diagnostics (HDII) re: FDA approval for their principle product announced last Friday):

Do they have partners?

HDI recently announced a collaboration with Pfizer for a multi-center drug research study (http://biz.yahoo.com/prnews/001025/mn_hyperte.html ). This is in addition to a study announced earlier with Solvay (http://biz.yahoo.com/prnews/000926/mn_hyperte.html ). Also, while not strictly a partner, they will gaining additional exposure through their participation in a NIH/NHLBI multi-site of atherosclerosis study (http://biz.yahoo.com/prnews/001017/mn_hyperte.html ).

Can their equipment be put into hospital modules?/ Is it quick or easy to use?

Go to the ‘products’ page of their website (http://www.hdi-pulsewave.com/). From all appearances, I would say an emphatic yes to both questions.

Is there a reimbursable mechanism in place that is cost effective to medical institutions or doctors. Are their recurring costs for each treatment to HDI?

I am unfamiliar with those issues at the moment. However, since a version of their device is already marketed in Europe, I would feel safe in assume they’ve established a cost effective mechanism for reimbursement. I am unaware if this mechanism will translate into the US health care system.

However, IMO, the advantages of a *non-invasive* cardiovascular profiling system will significantly enhance the likelihood the device will be perceived as eminently reimbursable.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News